Clinical, laboratory, and treatment characteristics of PTNFL and LSTFL cases included in this series
| . | PTNFL . | LSTFL . | P . | PTNFL ≤18 . | PTNFL >18 . | P . |
|---|---|---|---|---|---|---|
| N (%) . | N (%) . | PTNFL vs typical FL . | N (%) . | N (%) . | PTNFL <18 vs >18 . | |
| Number of cases | 26 | 18 | 16 | 10 | ||
| Male:female | 24:2 | 5:13 | <.0001 | 16:0 | 8:2 | .14 |
| Median age, y (range) | 16.0 (4-60) | 62.9 (33-85) | <.0001 | 14.7 (4-18) | 30 (20-60) | <.0001 |
| Age >18 y | 10 (38) | 18 (100) | <.0001 | 0 | 10 (100) | |
| Stage | .008 | 1 | ||||
| I | 26 (100) | 13 (72) | 14 (100) | 9 (100) | ||
| II | 0 | 5 (28) | 0 | 0 | ||
| Nodal location | ||||||
| Head and neck | 24 (92) | 4 (22) | <.0001 | 15 (94) | 9 (90) | 1 |
| Supraclavicular | 1 (4) | 0 | 1 (6) | 0 | ||
| Inguinal | 1 (4) | 9 (50) | 0 | 1 (10) | ||
| Axillary | 0 | 1 (6) | 0 | 0 | ||
| Other* | 0 | 4 (22) | 0 | 0 | ||
| Grade | ||||||
| 1-2 | 2 (8) | 15 (83) | 0 | 2 (20) | ||
| 3 | 24/26 (92) | 3 (17) | 16/16 | 8 (80) | ||
| Immunohistochemistry | ||||||
| CD10+ | 26/26 (100) | 17/18 (94) | .41 | 16/16 (100) | 10/10 (100) | 1 |
| BCL6+ | 26/26 (100) | 16/16 (100) | 1 | 16/16 (100) | 10/10 (100) | 1 |
| BCL2+ | 1/26 (4) | 16/18 (89) | <.0001 | 1/16 (6) | 0/10 (0) | 1 |
| MUM1+ | 0/26 (0) | 0/18 (0) | 1 | 0/16 (0) | 0/10 (0) | 1 |
| PI >30% (Ki-67) | 26/26 (100) | 5/15 (33) | <.0001 | 16/16 (100) | 10/10 (100) | 1 |
| Gene rearrangements | ||||||
| BCL2 rearrangement | 0/26 (0) | 16/18 (89) | <.0001 | 0 | 0 | 1 |
| BCL6 rearrangement | 0/26 (0) | 2/16 (13) | .1617 | 0 | 0 | 1 |
| Therapeutic approach | <.001 | <.01 | ||||
| Excision alone | 17 (65) | 2 (11) | 14 (88) | 3 (30) | ||
| Excision + rituximab | 1 (4) | 1 (6) | 1 (6) | 0 | ||
| Local RT (25-36 Gy) | 3 (12) | 11 (61) | 0 | 3 (30) | ||
| R-CHOP/+/−IFRT | 3 (12) | 4 (22) | 0 | 3 (30) | ||
| Unknown | 2 (8) | 0 | 1 (6) | 1 (10) | ||
| Outcome | ||||||
| Follow-up (mo) | 39 (4-126) | 38 (10-144) | .94 | 26 (4-126) | 43 (6-101) | .31 |
| Remission/NED | 24 (92) | 7 (35) | <.0001 | 15 (94) | 9 (90) | 1 |
| Recurrence/progression | 0 | 11 (65) | 0 | 0 | ||
| Unknown | 2 (8) | 0 | 1 (6) | 1 (10) | ||
| Transformation | 0 | 3 (18) | <.05 | 0 | 0 | 1 |
| . | PTNFL . | LSTFL . | P . | PTNFL ≤18 . | PTNFL >18 . | P . |
|---|---|---|---|---|---|---|
| N (%) . | N (%) . | PTNFL vs typical FL . | N (%) . | N (%) . | PTNFL <18 vs >18 . | |
| Number of cases | 26 | 18 | 16 | 10 | ||
| Male:female | 24:2 | 5:13 | <.0001 | 16:0 | 8:2 | .14 |
| Median age, y (range) | 16.0 (4-60) | 62.9 (33-85) | <.0001 | 14.7 (4-18) | 30 (20-60) | <.0001 |
| Age >18 y | 10 (38) | 18 (100) | <.0001 | 0 | 10 (100) | |
| Stage | .008 | 1 | ||||
| I | 26 (100) | 13 (72) | 14 (100) | 9 (100) | ||
| II | 0 | 5 (28) | 0 | 0 | ||
| Nodal location | ||||||
| Head and neck | 24 (92) | 4 (22) | <.0001 | 15 (94) | 9 (90) | 1 |
| Supraclavicular | 1 (4) | 0 | 1 (6) | 0 | ||
| Inguinal | 1 (4) | 9 (50) | 0 | 1 (10) | ||
| Axillary | 0 | 1 (6) | 0 | 0 | ||
| Other* | 0 | 4 (22) | 0 | 0 | ||
| Grade | ||||||
| 1-2 | 2 (8) | 15 (83) | 0 | 2 (20) | ||
| 3 | 24/26 (92) | 3 (17) | 16/16 | 8 (80) | ||
| Immunohistochemistry | ||||||
| CD10+ | 26/26 (100) | 17/18 (94) | .41 | 16/16 (100) | 10/10 (100) | 1 |
| BCL6+ | 26/26 (100) | 16/16 (100) | 1 | 16/16 (100) | 10/10 (100) | 1 |
| BCL2+ | 1/26 (4) | 16/18 (89) | <.0001 | 1/16 (6) | 0/10 (0) | 1 |
| MUM1+ | 0/26 (0) | 0/18 (0) | 1 | 0/16 (0) | 0/10 (0) | 1 |
| PI >30% (Ki-67) | 26/26 (100) | 5/15 (33) | <.0001 | 16/16 (100) | 10/10 (100) | 1 |
| Gene rearrangements | ||||||
| BCL2 rearrangement | 0/26 (0) | 16/18 (89) | <.0001 | 0 | 0 | 1 |
| BCL6 rearrangement | 0/26 (0) | 2/16 (13) | .1617 | 0 | 0 | 1 |
| Therapeutic approach | <.001 | <.01 | ||||
| Excision alone | 17 (65) | 2 (11) | 14 (88) | 3 (30) | ||
| Excision + rituximab | 1 (4) | 1 (6) | 1 (6) | 0 | ||
| Local RT (25-36 Gy) | 3 (12) | 11 (61) | 0 | 3 (30) | ||
| R-CHOP/+/−IFRT | 3 (12) | 4 (22) | 0 | 3 (30) | ||
| Unknown | 2 (8) | 0 | 1 (6) | 1 (10) | ||
| Outcome | ||||||
| Follow-up (mo) | 39 (4-126) | 38 (10-144) | .94 | 26 (4-126) | 43 (6-101) | .31 |
| Remission/NED | 24 (92) | 7 (35) | <.0001 | 15 (94) | 9 (90) | 1 |
| Recurrence/progression | 0 | 11 (65) | 0 | 0 | ||
| Unknown | 2 (8) | 0 | 1 (6) | 1 (10) | ||
| Transformation | 0 | 3 (18) | <.05 | 0 | 0 | 1 |
P values designating statistical significance are highlighted bold and italics.
IFRT, involved field RT; NED, no evidence of disease; PI, proliferation index; R-CHOP, rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone; RT, radiation therapy.
Other includes saphenous, femoral, abdominal, and antecubital lymph nodes.